Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Company Overview

Webcast ImageWebcast
Q2 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call (Replay)
07/30/15 at 9:00 a.m. ET
Q2 2015 Pacira Pharmaceuticals, Inc. Earnings Conference Call
Thursday, July 30, 2015 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$61.80
Change (%) Stock is Up 3.10 (5.28%)
Volume2,383,658
Data as of 07/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
07/30/15Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 30, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2015. “We recorded $57 million in EXPAREL product revenues in the second quarter, an increase o... 
Printer Friendly Version
07/15/15Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 15, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc. (NASDAQ: PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs. The randomized, blinded, multicenter pivotal study in dogs undergoing knee surger... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 30, 2015, at 9 a.m. ET. The call can be acc... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development. Dr. Braunstein brings over 20 years of knowledge and experience from his time both as a practicing physician and investor, as well as expertise from numerous commercial, consulting and operational roles advi... 
Printer Friendly Version

Corporate Presentation

DateTitle
06/02/15
Corporate Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com